Childhood acute lymphocytic leukemia.
At present, significant numbers of children with ALL enjoy prolonged survival without serious sequelae. All children should be given the benefit of treatment under the supervision of physicians experienced in childhood cancer. Risk factors should be properly assessed and children at high risk placed in innovative programs. Longterm follow-up of patients is essential to detect, as early as possible, potentially prohibitive toxicity.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002493:Central Nervous System Diseases / Q000628:therapy; D002648:Child; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000523:psychology / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology; D011379:Prognosis; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents